Regrettably, the phase I/II trial that utilized autologous DCs loaded with amplified ovarian cancer stem cell mRNA, hTERT, and survivin in recurrent platinum-sensitive epithelial ovarian cancer patients was terminated in 2021 (NCT01334047), with no results disclosed. The gene discussed is BIRC5; the disease is ovarian carcinoma.